Targeting IAP proteins in combination with radiotherapy

Overview of attention for article published in Radiation Oncology, April 2015

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 14 Dimensions

Readers on

mendeley: 18 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 14 publications that cite this research output.

14

The most recent citing publications are shown below. View all 14 publications that cite this research output on Dimensions.

Model‐Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Article in Clinical Pharmacology & Therapeutics (October 2023)

Influence of Perinatal Factors on Gene Expression of IAPs Family and Main Factors of Pluripotency: OCT4 and SOX2 in Human Breast Milk Stem Cells—A Preliminary Report

Article in International Journal of Molecular Sciences (January 2023)

Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial

Article in European Journal of Cancer (January 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.